Actavis PLC (ACT)

ACT on New York Consolidated

234.84USD
15 Sep 2014
Price Change (% chg)

$0.46 (+0.20%)
Prev Close
$234.38
Open
$233.62
Day's High
$235.80
Day's Low
$232.51
Volume
1,609,459
Avg. Vol
2,318,581
52-wk High
$239.15
52-wk Low
$135.50

ACT

Chart for ACT

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.36
Market Cap (Mil.): $61,937.43
Shares Outstanding (Mil.): 264.26
Dividend: --
Yield (%): --

Financials

  ACT Industry Sector
P/E (TTM): 502.19 32.65 33.52
EPS (TTM): 0.47 -- --
ROI: 0.38 18.10 17.33
ROE: 0.94 18.80 18.19
Search Stocks

NY attorney general sues Actavis and Forest Labs over Alzheimer's drug

- The attorney general of New York filed a lawsuit against Actavis Plc and its subsidiary to stop the companies from discontinuing its Alzheimer's drug, alleging that they were trying to maintain a monopoly position illegally.

9:29pm EDT

NY attorney general sues Actavis and Forest Labs over Alzheimer's drug

Sept 15 - The attorney general of New York filed a lawsuit against Actavis Plc and its subsidiary to stop the companies from discontinuing its Alzheimer's drug, alleging that they were trying to maintain a monopoly position illegally.

9:27pm EDT

Drugmaker Actavis forecasts profit below estimates

- Generic drug maker Actavis Plc's full-year profit forecast missed analysts' estimates, sending its shares down about 3 percent in premarket trading.

05 Aug 2014

REFILE-UPDATE 1-Drugmaker Actavis forecasts profit below estimates

Aug 5 - Generic drug maker Actavis Plc's full-year profit forecast missed analysts' estimates, sending its shares down about 3 percent in premarket trading.

05 Aug 2014

Drugmaker Actavis posts 34 pct rise in revenue

Aug 5 - Generic drug maker Actavis Plc's quarterly revenue rose 34 percent due to strong growth in its North America business.

05 Aug 2014

UPDATE 3-AstraZeneca buys Almirall lung drugs for up to $2.1 billion

* Initial $875 mln payout, up to $1.22 bln more if goals hit

30 Jul 2014

U.S. allows Actavis Plc's purchase of Forest Labs with conditions

WASHINGTON - Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

30 Jun 2014

UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions

(Adds details of drugs to be divested, share price, other pharma deals)

30 Jun 2014

U.S. allows Actavis Plc's purchase of Forest Labs with conditions

WASHINGTON, June 30 - Pharmaceutical company Actavis Plc has won U.S. approval to buy Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

30 Jun 2014

Acorda's multiple sclerosis drug faces generic threat

June 26 - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.

26 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks